109 related articles for article (PubMed ID: 22985491)
1. Combined targeting of MEK/MAPK and PI3K/Akt signalling in multiple myeloma.
Steinbrunn T; Stühmer T; Sayehli C; Chatterjee M; Einsele H; Bargou RC
Br J Haematol; 2012 Nov; 159(4):430-40. PubMed ID: 22985491
[TBL] [Abstract][Full Text] [Related]
2. Activated MEK cooperates with Ink4a/Arf loss or Akt activation to induce gliomas in vivo.
Robinson JP; Vanbrocklin MW; Lastwika KJ; McKinney AJ; Brandner S; Holmen SL
Oncogene; 2011 Mar; 30(11):1341-50. PubMed ID: 21057530
[TBL] [Abstract][Full Text] [Related]
3. Mutations and deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades which alter therapy response.
McCubrey JA; Steelman LS; Chappell WH; Abrams SL; Montalto G; Cervello M; Nicoletti F; Fagone P; Malaponte G; Mazzarino MC; Candido S; Libra M; Bäsecke J; Mijatovic S; Maksimovic-Ivanic D; Milella M; Tafuri A; Cocco L; Evangelisti C; Chiarini F; Martelli AM
Oncotarget; 2012 Sep; 3(9):954-87. PubMed ID: 23006971
[TBL] [Abstract][Full Text] [Related]
4. Rapid induction of apoptosis by PI3K inhibitors is dependent upon their transient inhibition of RAS-ERK signaling.
Will M; Qin AC; Toy W; Yao Z; Rodrik-Outmezguine V; Schneider C; Huang X; Monian P; Jiang X; de Stanchina E; Baselga J; Liu N; Chandarlapaty S; Rosen N
Cancer Discov; 2014 Mar; 4(3):334-47. PubMed ID: 24436048
[TBL] [Abstract][Full Text] [Related]
5. Synthetic Lethal Interaction of SHOC2 Depletion with MEK Inhibition in RAS-Driven Cancers.
Sulahian R; Kwon JJ; Walsh KH; Pailler E; Bosse TL; Thaker M; Almanza D; Dempster JM; Pan J; Piccioni F; Dumont N; Gonzalez A; Rennhack J; Nabet B; Bachman JA; Goodale A; Lee Y; Bagul M; Liao R; Navarro A; Yuan TL; Ng RWS; Raghavan S; Gray NS; Tsherniak A; Vazquez F; Root DE; Firestone AJ; Settleman J; Hahn WC; Aguirre AJ
Cell Rep; 2019 Oct; 29(1):118-134.e8. PubMed ID: 31577942
[TBL] [Abstract][Full Text] [Related]
6. Isoform- and Phosphorylation-specific Multiplexed Quantitative Pharmacodynamics of Drugs Targeting PI3K and MAPK Signaling in Xenograft Models and Clinical Biopsies.
Herrick WG; Kilpatrick CL; Hollingshead MG; Esposito D; O'Sullivan Coyne G; Gross AM; Johnson BC; Chen AP; Widemann BC; Doroshow JH; Parchment RE; Srivastava AK
Mol Cancer Ther; 2021 Apr; 20(4):749-760. PubMed ID: 33536190
[TBL] [Abstract][Full Text] [Related]
7. Relapsed neuroblastomas show frequent RAS-MAPK pathway mutations.
Eleveld TF; Oldridge DA; Bernard V; Koster J; Colmet Daage L; Diskin SJ; Schild L; Bentahar NB; Bellini A; Chicard M; Lapouble E; Combaret V; Legoix-Né P; Michon J; Pugh TJ; Hart LS; Rader J; Attiyeh EF; Wei JS; Zhang S; Naranjo A; Gastier-Foster JM; Hogarty MD; Asgharzadeh S; Smith MA; Guidry Auvil JM; Watkins TB; Zwijnenburg DA; Ebus ME; van Sluis P; Hakkert A; van Wezel E; van der Schoot CE; Westerhout EM; Schulte JH; Tytgat GA; Dolman ME; Janoueix-Lerosey I; Gerhard DS; Caron HN; Delattre O; Khan J; Versteeg R; Schleiermacher G; Molenaar JJ; Maris JM
Nat Genet; 2015 Aug; 47(8):864-71. PubMed ID: 26121087
[TBL] [Abstract][Full Text] [Related]
8. Ras drives malignancy through stem cell crosstalk with the microenvironment.
Yuan S; Stewart KS; Yang Y; Abdusselamoglu MD; Parigi SM; Feinberg TY; Tumaneng K; Yang H; Levorse JM; Polak L; Ng D; Fuchs E
Nature; 2022 Dec; 612(7940):555-563. PubMed ID: 36450983
[TBL] [Abstract][Full Text] [Related]
9. RAL GTPases mediate multiple myeloma cell survival and are activated independently of oncogenic RAS.
Seibold M; Stühmer T; Kremer N; Mottok A; Scholz CJ; Schlosser A; Leich E; Holzgrabe U; Brünnert D; Barrio S; Kortüm MK; Solimando AG; Chatterjee M; Einsele H; Rosenwald A; Bargou RC; Steinbrunn T
Haematologica; 2020 Sep; 105(9):2316-2326. PubMed ID: 33054056
[TBL] [Abstract][Full Text] [Related]
10. Ras-related and MAPK signalling in neuronal plasticity and memory formation.
Mazzucchelli C; Brambilla R
Cell Mol Life Sci; 2000 Apr; 57(4):604-11. PubMed ID: 11130460
[TBL] [Abstract][Full Text] [Related]
11. Collagen from Iris squid grafted with polyethylene glycol and collagen peptides promote the proliferation of fibroblast through PI3K/AKT and Ras/RAF/MAPK signaling pathways.
Hou C; Lei Y; Li N; Wei M; Wang S; Rahman SU; Bao C; Bao B; Elango J; Wu W
Int J Biol Macromol; 2023 Aug; 247():125772. PubMed ID: 37429348
[TBL] [Abstract][Full Text] [Related]
12. The genetic landscape of 5T models for multiple myeloma.
Maes K; Boeckx B; Vlummens P; De Veirman K; Menu E; Vanderkerken K; Lambrechts D; De Bruyne E
Sci Rep; 2018 Oct; 8(1):15030. PubMed ID: 30301958
[TBL] [Abstract][Full Text] [Related]
13. Modulation of the Akt/Ras/Raf/MEK/ERK pathway by A₃ adenosine receptor.
Merighi S; Benini A; Mirandola P; Gessi S; Varani K; Leung E; Maclennan S; Baraldi PG; Borea PA
Purinergic Signal; 2006 Nov; 2(4):627-32. PubMed ID: 18404465
[TBL] [Abstract][Full Text] [Related]
14. Divergent effects of intrinsically active MEK variants on developmental Ras signaling.
Goyal Y; Jindal GA; Pelliccia JL; Yamaya K; Yeung E; Futran AS; Burdine RD; Schüpbach T; Shvartsman SY
Nat Genet; 2017 Mar; 49(3):465-469. PubMed ID: 28166211
[TBL] [Abstract][Full Text] [Related]
15. Pathway-Directed Therapy in Multiple Myeloma.
John L; Krauth MT; Podar K; Raab MS
Cancers (Basel); 2021 Apr; 13(7):. PubMed ID: 33916289
[TBL] [Abstract][Full Text] [Related]
16. Glutamatergic Signaling a Therapeutic Vulnerability in Melanoma.
Eddy K; Chen S
Cancers (Basel); 2021 Jul; 13(15):. PubMed ID: 34359771
[TBL] [Abstract][Full Text] [Related]
17. Targeted sequencing of refractory myeloma reveals a high incidence of mutations in CRBN and Ras pathway genes.
Kortüm KM; Mai EK; Hanafiah NH; Shi CX; Zhu YX; Bruins L; Barrio S; Jedlowski P; Merz M; Xu J; Stewart RA; Andrulis M; Jauch A; Hillengass J; Goldschmidt H; Bergsagel PL; Braggio E; Stewart AK; Raab MS
Blood; 2016 Sep; 128(9):1226-33. PubMed ID: 27458004
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study.
Nogova L; Sequist LV; Perez Garcia JM; Andre F; Delord JP; Hidalgo M; Schellens JH; Cassier PA; Camidge DR; Schuler M; Vaishampayan U; Burris H; Tian GG; Campone M; Wainberg ZA; Lim WT; LoRusso P; Shapiro GI; Parker K; Chen X; Choudhury S; Ringeisen F; Graus-Porta D; Porter D; Isaacs R; Buettner R; Wolf J
J Clin Oncol; 2017 Jan; 35(2):157-165. PubMed ID: 27870574
[TBL] [Abstract][Full Text] [Related]
19. A Landscape of Pharmacogenomic Interactions in Cancer.
Iorio F; Knijnenburg TA; Vis DJ; Bignell GR; Menden MP; Schubert M; Aben N; Gonçalves E; Barthorpe S; Lightfoot H; Cokelaer T; Greninger P; van Dyk E; Chang H; de Silva H; Heyn H; Deng X; Egan RK; Liu Q; Mironenko T; Mitropoulos X; Richardson L; Wang J; Zhang T; Moran S; Sayols S; Soleimani M; Tamborero D; Lopez-Bigas N; Ross-Macdonald P; Esteller M; Gray NS; Haber DA; Stratton MR; Benes CH; Wessels LFA; Saez-Rodriguez J; McDermott U; Garnett MJ
Cell; 2016 Jul; 166(3):740-754. PubMed ID: 27397505
[TBL] [Abstract][Full Text] [Related]
20. Incorporation of Next-Generation Sequencing into Routine Clinical Care to Direct Treatment of Head and Neck Squamous Cell Carcinoma.
Chau NG; Li YY; Jo VY; Rabinowits G; Lorch JH; Tishler RB; Margalit DN; Schoenfeld JD; Annino DJ; Goguen LA; Thomas T; Becker H; Haddad T; Krane JF; Lindeman NI; Shapiro GI; Haddad RI; Hammerman PS
Clin Cancer Res; 2016 Jun; 22(12):2939-49. PubMed ID: 26763254
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
